Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy

Clinical Cancer Research

Volumn 23, Issue 3, 2017, Pages 658-665

  Shachar, Shlomit Strulov ^a,b   Deal, Allison M ^a   Weinberg, Marc ^a   Nyrop, Kirsten A ^a   Williams, Grant R ^a   Nishijima, Tomohiro F ^a   Benbow, Julia M ^a   Muss, Hyman B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Division of Oncology   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGE; ANEMIA; ARTICLE; BODY MASS; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE ASSOCIATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; LEAN BODY WEIGHT; LUMBAR VERTEBRA; METASTATIC BREAST CANCER; MUSCULOSKELETAL SYSTEM PARAMETERS; NEUROTOXICITY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; SARCOPENIA; SKELETAL MUSCLE DENSITY; SKELETAL MUSCLE GAUGE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; ADENOCARCINOMA; AGED; BODY COMPOSITION; BREAST TUMOR; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; ORGAN SIZE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RELATIVE DENSITY; SECONDARY; SKELETAL MUSCLE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY COMPOSITION; BODY MASS INDEX; BODY SURFACE AREA; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUSCLE, SKELETAL; ORGAN SIZE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SARCOPENIA; SPECIFIC GRAVITY; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85012280744     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0940     Document Type: Article

References (41)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
3. Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, Greco M, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 1995;87:19-27.
4. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast 2012;21:242-52.
5. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998;147:755-63.
6. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 2016;57:58-67.
7. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920-6.
8. Wong AL, Seng KY, Ong EM, Wang LZ, Oscar H, Cordero MT, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat 2014;144:143-52.
9. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
10. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. The N Engl J Med 2015;372:724-34.
11. Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 data files 2015 [Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
12. Popuri K, Cobzas D, Esfandiari N, Baracos V, Jagersand M. Body composition assessment in axial CT images using FEM-based automatic segmentation of skeletal muscle. IEEE Trans Med Imaging 2015;35:512-20.
13. Chung H, Cobzas D, Birdsell L, Lieffers J, Baracos Veditors. Automated segmentation of muscle and adipose tissue on CT images for human body composition analysis. SPIE Medical Imaging; 2009: International Society for Optics and Photonics.
14. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539-47.
15. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol 2014;210:489-97.
16. Tamandl D, Paireder M, Asari R, Baltzer PA, Schoppmann SF, Ba-Ssalamah A. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol 2016;26:1359-67.
17. Blauwhoff-Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 2016;34:1339-44.
18. Weinberg M, Shachar S, Deal A, Williams G, Nyrop K, Alston S, et al. Characterization of skeletal muscle and body mass indices in younger and older women with stage II and III breast cancer. J Am Geriatr Soc 2016; supplement:S86.
19. Alsharedi M, Gress T, Dotson J, Elmsherghi N, Tirona MT. Comparison of toxicity profile and tolerability between two standard of care paclitaxel-based adjuvant chemotherapy regimens in breast cancer. Med Oncol 2016;33:27.
20. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, et al. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 2011;67: 93-101.
21. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 2007; 13:3264-8.
22. Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol 2015; 41:333-8.
23. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010;21:1594-8.
24. Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, et al. Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 2014;66:583-9.
25. Cushen SJ, Power DG, Teo MY, Maceneaney P, Maher MM, McDermott R, et al. Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol 2014:Epub Ahead of Print.
26. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 2013;108:1034-41.
27. Massicotte MH, Borget I, Broutin S, Baracos VE, Leboulleux S, Baudin E, et al. Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab 2013;98:2401-8.
28. Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 2016;54:2-10.
29. Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research. J Clin Oncol 2014;32:2611-6.
30. Du BD, Du BE. Clinical calorimetry: Tenth paper a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916;XVII:863-71.
31. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 2012;51:319-30.
32. Ratain MJ.Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol 1998;16:2297-8.
33. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629-35.
34. Maddocks M, Murton AJ, Wilcock A. Improvingmuscle mass and function in cachexia: non-drug approaches. Curr Opin Support Palliat Care 2011;5:361-4.
35. Argiles JM, Busquets S, Lopez-Soriano FJ, Costelli P, Penna F. Are there any benefits of exercise training in cancer cachexia? J Cachexia, Sarcopenia Muscle 2012;3:73-6.
36. Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol 2015;22:100-6.
37. Kung T, Springer J, Doehner W, Anker SD, von Haehling S. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference. Expert Opin Investig Drugs 2010;19:579-85.
38. Di Girolamo FG, Situlin R, Mazzucco S, Valentini R, Toigo G, Biolo G. Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia. Curr Opin Clin Nutr Metab Care 2014;17:145-50.
39. Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, et al. The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle 2011;2:163-74.
40. Berardi E, Annibali D, Cassano M, Crippa S, Sampaolesi M.Molecular and cell-based therapies for muscle degenerations: a road under construction. Front Physiol 2014;5:119.
41. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 2016;17:519-31.